{
    "Clinical Trial ID": "NCT00496860",
    "Intervention": [
        "INTERVENTION 1: ",
        "  ALT-801 0.015 mg/kg/Dose",
        "  0.015 mg/kg/dose of ALT-801",
        "INTERVENTION 2: ",
        "  ALT-801 0.040 mg/kg/Dose",
        "  0.040 mg/kg/dose of ALT-801"
    ],
    "Eligibility": [
        "ENTRY CRITERIA:",
        "  DISEASE CHARACTERISTICS:",
        "  Locally advanced or metastatic malignancies",
        "  Histologically or cytologically confirmed",
        "  Evaluable",
        "  Surgically and medically incurable",
        "  Not responding to standard therapy or no other standard therapy exists",
        "  Human leukocyte antigen (HLA)-A2.1/p53 positive",
        "  PRIOR/CONCURRENT THERAPY:",
        "  No prior Proleukin therapy within one year",
        "  No concurrent radiotherapy, chemotherapy, or other immunotherapy",
        "  More than 4 weeks since prior major radiotherapy",
        "  More than 4 weeks since prior cytotoxic therapy",
        "  More than 6 weeks since prior nitrosoureas therapy",
        "  More than 8 weeks since prior monoclonal antibody therapy",
        "  PATIENT CHARACTERISTICS:",
        "  Life expectancy",
        "  > 3 months",
        "  Performance status",
        "  Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1",
        "  Bone marrow reserve",
        "  Absolute neutrophil count (AGC/ANC)  1,500/microliters (uL)",
        "  Platelets 100,000/uL",
        "  Hemoglobin  10g/dL",
        "  Renal function",
        "  Serum creatinine  1.5 X Upper limit of normal (ULN)",
        "  Hepatic function",
        "  Total bilirubin  1.5 X ULN",
        "  Aspartate Aminotransferase (AST)  2.5 X ULN",
        "  Alkaline phosphatase  2.5 X ULN",
        "  Prothrombin time (PT) or international normalized ratio (INR)  1.5 X ULN",
        "  Activated partial thromboplastin time (aPTT)  1.5 X ULN",
        "  Cardiovascular",
        "  May be safely tapered off anti-hypertensives if currently on anti-hypertensives",
        "  New York Heart Association classification I or II",
        "  No congestive heart failure <6 months",
        "  No unstable angina pectoris <6 months",
        "  No myocardial infarction <6 months",
        "  No history of ventricular arrhythmias",
        "  Normal cardiac stress test required if any of the following is present:",
        "  Over age 50",
        "  History of abnormal EKG",
        "  Symptoms of cardiac ischemia or arrhythmia",
        "  Pulmonary",
        "  Normal pulmonary function test (FEV1  75% of predicted value) if any of the following is present:",
        "  Prolonged history of cigarette smoking",
        "  Symptoms of respiratory dysfunction",
        "  Other",
        "  No known autoimmune disease",
        "  No known HIV positive",
        "  No psychiatric illness/social situations that would limit study compliance",
        "  No history or evidence of central nervous system (CNS) disease",
        "  No active systemic infection requiring parental antibiotic therapy",
        "  No systemic steroid therapy required",
        "  No prior organ allograft",
        "  Not receiving other investigational agents",
        "  Not receiving chronic medication for asthma",
        "  Not pregnant or nursing",
        "  Fertile patients must use effective contraception"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  The Safety and Toxicity of ALT-801 in Patients With Progressive Metastatic Malignancies",
        "  Number of serious adverse events per cohort",
        "  Time frame: 18 months",
        "Results 1: ",
        "  Arm/Group Title: ALT-801 0.015 mg/kg/Dose",
        "  Arm/Group Description: 0.015 mg/kg/dose of ALT-801",
        "  Overall Number of Participants Analyzed: 4",
        "  Measure Type: Number",
        "  Unit of Measure: Events  0",
        "Results 2: ",
        "  Arm/Group Title: ALT-801 0.040 mg/kg/Dose",
        "  Arm/Group Description: 0.040 mg/kg/dose of ALT-801",
        "  Overall Number of Participants Analyzed: 16",
        "  Measure Type: Number",
        "  Unit of Measure: Events  2"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 0/4 (0.00%)",
        "  Thrombocytopenia0/4 (0.00%)",
        "  Cardiac Ischemia/Infarction0/4 (0.00%)",
        "  Death-NOS0/4 (0.00%)",
        "  Pleural Effusion0/4 (0.00%)",
        "  Pulmonary Infiltrates0/4 (0.00%)",
        "Adverse Events 2:",
        "  Total: 2/16 (12.50%)",
        "  Thrombocytopenia0/16 (0.00%)",
        "  Cardiac Ischemia/Infarction0/16 (0.00%)",
        "  Death-NOS1/16 (6.25%)",
        "  Pleural Effusion1/16 (6.25%)",
        "  Pulmonary Infiltrates0/16 (0.00%)"
    ]
}